91832-40-5 Usage
Description
Cefdinir is an orally active, beta-lactamase stable cephalosporin antibiotic with a broad spectrum of activity. It is effective against a wide range of Gram-positive and Gram-negative bacteria, including β-lactamase-producing strains such as E. coli, K. oxytoca, K. pneumoniae, and P. aeruginosa. Cefdinir is more potent against Gram-positive bacteria, particularly Staphylococci, compared to other oral cephalosporins.
Uses
Used in Pharmaceutical Industry:
Cefdinir is used as a broad-spectrum antibiotic for treating various Gram-positive and Gram-negative infections. Its effectiveness against a range of bacteria makes it a valuable treatment option for a variety of infections caused by susceptible pathogens.
Used in Medical Treatment:
Cefdinir is used as an antibiotic for the treatment of respiratory tract infections, skin infections, and other bacterial infections caused by susceptible strains of the targeted bacteria. Its broad-spectrum activity and beta-lactamase stability contribute to its efficacy in combating a wide range of bacterial infections.
Manufacturing Process
By interaction of 7-amino-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-
2-carboxylic acid 4-methoxyphenyl ester with 4-bromoacetyl bromide was
prepared 7-(4-bromo-3-oxo-butyrylamino)-8-oxo-3-vinyl-5-thia-1-azabicyclo
(4.2.0)oct-2-ene-2-carboxylic acid 4-methoxyphenyl ester. The active
methylene group in that product was then nitrosated with sodium nitrite. The
initial product spontaneously tautomerizes to afford 7-(4-bromo-2-
hydroxyimino-3-oxo-butyrylamino)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)
oct-2-ene-2-carboxylic acid 4-methoxyphenyl ester. By the reaction of that
compound with thiourea and then with trifluoroacetic acid was obtained
(6R,7R)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-
azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid sodium nitrite, (Z)-oxime
(Cefdinir sodium nitrile).In practice it is usually used as free acid.Synthesis of 7β-[2-(2-aminothiazol-4-yl)-2-(Z)-(trytiloxyimino)acetamido]-3-
vinyl-3-cephem-4-carboxylic acid x p-toluenesulfonic acid x 2 N,N-dimethylacetamide (the precursor of Cefdinir) was described in Patent US
6,093,814.
Therapeutic Function
Antibiotic
Antimicrobial activity
An oral cephalosporin similar in structure to cefixime, but
with a slightly modified side chain at the 7-amino position.
Activity is similar to that of cefixime, but it is more active,
especially against staphylococci. It is not hydrolyzed
by staphylococcal or the common plasmid-mediated
enterobacterial β-lactamases. An enhancing effect on phagocytosis
has been demonstrated in vitro.
Oral absorption is about 35%. A 200 mg oral dose achieves
a plasma concentration of 1 mg/L after c. 3 h. Absorption is
reduced after a fatty meal. Concentrations equal to or higher
than corresponding plasma levels were present in blister fluid
6–12 h after administration of an oral dose. The plasma halflife
is 1.5 h. Protein binding is 60–70%. A total of 12–20%
of the dose was excreted in the urine within 12 h, the renal
elimination declining with increasing dose. The elimination
half-life and peak plasma concentration are increased in renal
failure. About 60% of the drug is removed by hemodialysis.
Side effects and uses are those common to oral
cephalosporins.
Safety Profile
Moderately toxic by ingestion andintravenous routes. Low toxicity by intraperitoneal andsubcutaneous routes. Experimental reproductive effects.When heated to decomposition it emits toxic vapors ofNOx and SOx.
Check Digit Verification of cas no
The CAS Registry Mumber 91832-40-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,1,8,3 and 2 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 91832-40:
(7*9)+(6*1)+(5*8)+(4*3)+(3*2)+(2*4)+(1*0)=135
135 % 10 = 5
So 91832-40-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
91832-40-5Relevant articles and documents
Method for preparing cefdinir
-
Paragraph 0032; 0033; 0034; 0035; 0036; 0037; 0038, (2017/07/21)
The invention relates to a method for preparing cefdinir. The method includes condensing active ester of methoxyiminoacetic acid and 7.amino.3.vinyl.3.cephalosporin ring.4.carboxylate ester in the presence of organic alkali; carrying out ester hydrolysis reaction. The method has the advantages of few reaction steps, high yield and simplicity in post-treatment.
Cefdinir synthesizing technology
-
Paragraph 0055; 0062-0074; 0081-0093; 0100-0112; 0119-0131, (2017/06/02)
The invention provides a cefdinir synthesizing technology. The technology comprises the steps that (Z)-2-(2-aminothiazole-4-yl)-2-acetoxyl imino thioacetic acid(S-2-benzothiazole)ester and 7-amino-3-vinyl-8-oxo-5-thia-1-azabicyalo[4.2.0]oct-2-alkene-2-carboxylic acid are subjected to condensation; acetyl protection is removed through hydrolysis, and a cefdinir finished product is finally obtained. The method for preparing the cefdinir has the advantages of being short in production cycle, high in yield, high in product quality and suitable for industrial production.
Process for the preparation of cefdinir
-
Page/Page column 4, (2008/06/13)
The invention relates to processes for preparing cefdinir via its potassium and cesium salts.